Literature DB >> 33753727

S-adenosylmethionine upregulates the angiotensin receptor-binding protein ATRAP via the methylation of HuR in NAFLD.

Tao Guo1, Zhe Dai2, Ke You3, Shyue-Fang Battaglia-Hsu4, Juan Feng5, Fengliang Wang6, Bao Li7, Jian Yang8, Zhen Li9.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) has emerged globally and is associated with inflammatory signaling. The underlying mechanisms remain poorly delineated, although NAFLD has attracted considerable attention and been extensively investigated. Recent publications have determined that angiotensin II (Ang II) plays an important role in stimulating NAFLD progression by causing lipid metabolism disorder and insulin resistance through its main receptor, Ang II type 1 receptor (AT1R). Herein, we explored the effect of supplementary S-adenosylmethionine (SAM), which is the main biological methyl donor in mammalian cells, in regulating AT1R-associated protein (ATRAP), which is the negative regulator of AT1R. We found that SAM was depleted in NAFLD and that SAM supplementation ameliorated steatosis. In addition, in both high-fat diet-fed C57BL/6 rats and L02 cells treated with oleic acid (OA), ATRAP expression was downregulated at lower SAM concentrations. Mechanistically, we found that the subcellular localization of human antigen R (HuR) was determined by the SAM concentration due to protein methylation modification. Moreover, HuR was demonstrated to directly bind ATRAP mRNA and control its nucleocytoplasmic shuttling. Thus, SAM was suggested to upregulate ATRAP protein expression by maintaining the export of its mRNA from the nucleus. Taken together, our findings suggest that SAM can positively regulate ATRAP in NAFLD and may have various potential benefits for the treatment of NAFLD.

Entities:  

Year:  2021        PMID: 33753727      PMCID: PMC7985363          DOI: 10.1038/s41419-021-03591-1

Source DB:  PubMed          Journal:  Cell Death Dis            Impact factor:   8.469


  59 in total

1.  Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease.

Authors:  Susan K Murphy; Hyuna Yang; Cynthia A Moylan; Herbert Pang; Andrew Dellinger; Manal F Abdelmalek; Melanie E Garrett; Allison Ashley-Koch; Ayako Suzuki; Hans L Tillmann; Michael A Hauser; Anna Mae Diehl
Journal:  Gastroenterology       Date:  2013-07-31       Impact factor: 22.682

2.  SNHG6 Acts as a Genome-Wide Hypomethylation Trigger via Coupling of miR-1297-Mediated S-Adenosylmethionine-Dependent Positive Feedback Loops.

Authors:  Tao Guo; Hongling Wang; Pengpeng Liu; Yushao Xiao; Ping Wu; Yitao Wang; Baiyang Chen; Qiu Zhao; Zhisu Liu; Quanyan Liu
Journal:  Cancer Res       Date:  2018-05-29       Impact factor: 12.701

Review 3.  Quantitative Hepatic Fat Quantification in Non-alcoholic Fatty Liver Disease Using Ultrasound-Based Techniques: A Review of Literature and Their Diagnostic Performance.

Authors:  Arinc Ozturk; Joseph R Grajo; Michael S Gee; Alex Benjamin; Rebecca E Zubajlo; Kai E Thomenius; Brian W Anthony; Anthony E Samir; Manish Dhyani
Journal:  Ultrasound Med Biol       Date:  2018-09-16       Impact factor: 2.998

4.  Behavioral and metabolic effects of S-adenosylmethionine and imipramine in the Flinders Sensitive Line rat model of depression.

Authors:  Sandra Tillmann; Denise F Happ; Per F Mikkelsen; Juergen Geisel; Gregers Wegener; Rima Obeid
Journal:  Behav Brain Res       Date:  2019-02-06       Impact factor: 3.332

5.  Protein arginine methyltransferases: guardians of the Arg?

Authors:  Frank O Fackelmayer
Journal:  Trends Biochem Sci       Date:  2005-10-27       Impact factor: 13.807

6.  Activation of the cardiac proteasome promotes angiotension II-induced hypertrophy by down-regulation of ATRAP.

Authors:  Nan Li; Hong-Xia Wang; Qiu-Yue Han; Wen-Jun Li; Yun-Long Zhang; Jie Du; Yun-Long Xia; Hui-Hua Li
Journal:  J Mol Cell Cardiol       Date:  2014-12-16       Impact factor: 5.000

7.  The angiotensin II type I receptor-associated protein, ATRAP, is a transmembrane protein and a modulator of angiotensin II signaling.

Authors:  Marco Lopez-Ilasaca; Xiushi Liu; Koichi Tamura; Victor J Dzau
Journal:  Mol Biol Cell       Date:  2003-09-05       Impact factor: 4.138

Review 8.  The obesity epidemic and nonalcoholic fatty liver disease in children.

Authors:  Winston Dunn; Jeffrey B Schwimmer
Journal:  Curr Gastroenterol Rep       Date:  2008-02

9.  Dihydromyricetin ameliorates oleic acid-induced lipid accumulation in L02 and HepG2 cells by inhibiting lipogenesis and oxidative stress.

Authors:  Caifeng Xie; Zhen Chen; Chengfu Zhang; Xin Xu; Jiangbo Jin; Weihua Zhan; Tianyu Han; Jianbin Wang
Journal:  Life Sci       Date:  2016-06-03       Impact factor: 5.037

10.  S-adenosylmethionine deficiency and TNF-alpha in lipopolysaccharide-induced hepatic injury.

Authors:  R K Chawla; W H Watson; C E Eastin; E Y Lee; J Schmidt; C J McClain
Journal:  Am J Physiol       Date:  1998-07
View more
  3 in total

1.  A liver secretome gene signature-based approach for determining circulating biomarkers of NAFLD severity.

Authors:  Christoffer A Hagemann; Christian Legart; Mathias B Møllerhøj; Martin R Madsen; Henrik H Hansen; Merete J Kønig; Frederik Helgstrand; Flemming P Hjørne; Anders Toxværd; Jill L Langhoff; Urd L Kielgast; Lise L Gluud; Helene Ægidius; Kristoffer T G Rigbolt; Tina Vilsbøll; Jacob Jelsing; Filip K Knop
Journal:  PLoS One       Date:  2022-10-19       Impact factor: 3.752

2.  Hepatic PRMT1 ameliorates diet-induced hepatic steatosis via induction of PGC1α.

Authors:  Lu Xu; Zhe Huang; Tak-Ho Lo; Jimmy Tsz Hang Lee; Ranyao Yang; Xingqun Yan; Dewei Ye; Aimin Xu; Chi-Ming Wong
Journal:  Theranostics       Date:  2022-02-28       Impact factor: 11.600

3.  USF1-ATRAP-PBX3 Axis Promote Breast Cancer Glycolysis and Malignant Phenotype by Activating AKT/mTOR Signaling.

Authors:  Dandan Wang; Xiaoying Jin; Mengxia Lei; Ying Jiang; Yali Liu; Fei Yu; Yan Guo; Bing Han; Yue Yang; Weiling Sun; Ying Liu; Guangchun Zeng; Feng Liu; Jing Hu; Xuesong Chen
Journal:  Int J Biol Sci       Date:  2022-03-14       Impact factor: 6.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.